Key announcements: Raising FY25 non-GAAP diluted EPS guidance to $8.15 to$8.201 Establishing preliminary FY26 non-GAAP diluted EPS guidance of $9.10 to$9.30 (13% growth at the mid-points)2 Confirming long-term target of 12% to 14% non-GAAP diluted EPS CAGR for FY26 to FY283 Raising long-term target for Pharmaceutical and Specialty Solutions profit to 5% to 7% normalized growth3,4 Raising long-term target for Other profit to ~10% normalized growth3,4,5 Updating GMPD long-term target to $50M+ of profit grow ...